Altimmune, Inc. (NASDAQ:ALT) Given Average Rating of “Moderate Buy” by Analysts

Altimmune, Inc. (NASDAQ:ALT) has been assigned a consensus recommendation of “Moderate Buy” from the nine brokerages that are covering the company, MarketBeat.com reports. Two equities research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company. The average twelve-month price objective among analysts that have issued a report on the stock in the last year is $20.83.

Several equities research analysts have recently issued reports on the stock. HC Wainwright reissued a “buy” rating and set a $12.00 target price on shares of Altimmune in a research note on Tuesday, March 18th. Stifel Nicolaus began coverage on Altimmune in a research report on Wednesday, January 8th. They set a “buy” rating and a $18.00 price target on the stock. Finally, William Blair restated a “market perform” rating on shares of Altimmune in a research report on Friday, March 14th.

Altimmune Trading Down 0.4 %

Altimmune stock opened at $5.57 on Friday. The firm has a market cap of $428.97 million, a PE ratio of -3.59 and a beta of 0.87. Altimmune has a 12 month low of $5.14 and a 12 month high of $11.16. The stock’s 50 day simple moving average is $6.27 and its two-hundred day simple moving average is $7.06.

Altimmune (NASDAQ:ALT) last posted its earnings results on Thursday, February 27th. The company reported ($0.33) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.34) by $0.01. The firm had revenue of $0.01 million during the quarter, compared to analysts’ expectations of $0.00 million. Altimmune had a negative net margin of 199,076.92% and a negative return on equity of 55.81%. On average, equities research analysts forecast that Altimmune will post -1.35 EPS for the current year.

Insider Buying and Selling

In other news, CFO Gregory L. Weaver acquired 10,000 shares of the firm’s stock in a transaction on Thursday, March 13th. The shares were bought at an average price of $5.20 per share, for a total transaction of $52,000.00. Following the acquisition, the chief financial officer now owns 10,000 shares of the company’s stock, valued at approximately $52,000. This trade represents a ∞ increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through this hyperlink. 4.10% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Altimmune

Hedge funds have recently modified their holdings of the business. Larson Financial Group LLC purchased a new stake in Altimmune during the 3rd quarter valued at about $31,000. SBI Securities Co. Ltd. acquired a new position in shares of Altimmune during the 4th quarter worth approximately $45,000. Virtus ETF Advisers LLC purchased a new stake in shares of Altimmune in the fourth quarter valued at approximately $60,000. Cullen Frost Bankers Inc. acquired a new stake in shares of Altimmune in the fourth quarter valued at approximately $72,000. Finally, Sunbelt Securities Inc. lifted its position in Altimmune by 356.8% during the fourth quarter. Sunbelt Securities Inc. now owns 10,844 shares of the company’s stock worth $79,000 after buying an additional 8,470 shares in the last quarter. 78.05% of the stock is currently owned by institutional investors and hedge funds.

About Altimmune

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.